4//SEC Filing
Eisenberg Marcia 4
Accession 0000950170-25-027092
CIK 0001850906other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 8:04 PM ET
Size
8.4 KB
Accession
0000950170-25-027092
Insider Transaction Report
Form 4
Eisenberg Marcia
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21$8.84/sh−1,850$16,354→ 0 totalExercise: $11.16Exp: 2034-05-29→ Common Stock (1,850 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21−4,933→ 0 totalExercise: $22.41Exp: 2033-08-03→ Common Stock (4,933 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
- [F2]As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Documents
Issuer
Singular Genomics Systems, Inc.
CIK 0001850906
Entity typeother
Related Parties
1- filerCIK 0001866723
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 8:04 PM ET
- Size
- 8.4 KB